万古霉素单用与联用磷霉素治疗耐甲氧西林金黄色葡萄球菌肺部感染的疗效比较  

The Compare Study on Vancomycin with or without Fosfomycin in the Treatment of Pulmonary Infection with MRSA

作　　者：胡文 邓国泉 伍婷 何岚 胡金家[2] 

机构地区：[1]江西省宜春市人民医院临床药学室,宜春336000 [2]上海交通大学医学解剖学教研室,上海200025

出　　处：《实用中西医结合临床》2012年第4期6-7,共2页Practical Clinical Journal of Integrated Traditional Chinese and Western Medicine

摘　　要：目的:比较万古霉素单用与联用磷霉素治疗成人耐甲氧西林金黄色葡萄球菌(MRSA)肺部感染的疗效和安全性。方法:对27例联用万古霉素和磷霉素(治疗组)以及23例单用万古霉素(对照组)治疗MRSA肺部感染患者进行治疗前后的临床症状以及不良反应统计分析。结果:治疗组治疗MRSA肺部感染临床有效率为88.9%,对照组有效率为82.6%,两组临床疗效比较无明显差异(P>0.05),不良反应比较有显著差异(P<0.05)。结论:万古霉素与磷霉素联用,能明显减少患者的住院时间,减少不良反应的发生率,可作为治疗MRSA肺部感染的经验性用药之一。Objective：To compare the efficacy and safety of vancomycin with or without fosfomycin in adult pulmonary infection with methicillin resistant staphylococcus aureus （MRSA）.Methods：27 Patients in the treatment group received vancomycin and fosfomycin, and 23 patients in the compare group received vancomycin alone. The therapeutic effects and side effects were compared by statistical analysis.Results：The clinical effective rate of the treatment group was 88.9%,and the compare group was 82.6%.There was no obvious difference in clinical effect （P 〉0.05）,but significant difference in adverse reaction （P 〈0.05） between the two groups.Conclusion： The combination of vancomycin and fosfomycin could reduce the period in hospital obviously, decrease adverse reaction. So it could be used as one of the empirical medications of pulmonary infection with MRSA.

关 键 词：磷霉素 万古霉素 耐甲氧西林金黄色葡萄球菌 肺部感染 

分 类 号：R563[医药卫生—呼吸系统]